Combination Antibody Immunotherapy Targets Cancer Resistance
Existing cancer immunotherapies act on only a fraction of the immune cells implicated in the disease. In this study, the research team developed an antibody, KWAR23, to block a different set of immune cells known as myeloid cells. Many of these cells infiltrate tumors, triggering tumor growth, inflammation, and resistance to treatment. In both cell culture and in mouse models with human cell membrane proteins, the research team found that the antibody blocked a protein that would otherwise limit the tumor-killing ability of myeloid cells....